Pantoprazole Stada

Pantoprazole, the active ingredient in Pantoprazole Stada, is a proton pump inhibitor presented as a tablet for oral use. It reduces stomach acid production and is used to treat conditions such as gastro‑oesophageal reflux disease and peptic ulcer disease in adults.

GNH USA supplies Pantoprazole Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Pantoprazole Stada is used to manage acid‑related disorders by decreasing gastric acid secretion. It is indicated for: - Gastro‑oesophageal reflux disease (GERD): allevistrength  ​   ​  ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​​ - Peptic ulcer disease: promotes healing of gastric and duodenal ulcers by maintaining a less acidic environment. - Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with gastrin‑producing tumors. - Erosive esophagitis: aids in the healing of acid‑induced damage to the esophageal lining. - Maintenance therapy after ulcer healing: helps prevent recurrence of ulcers.

Pantoprazole may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate pain often described as tension‑type. - Diarrhea: loose, watery stools occurring intermittently. - Nausea: sensation of unease or urge to vomit. - Abdominal pain: cramping or discomfort in the stomach region. - Flatulence: excess gas leading to bloating. - Constipation: infrequent or difficult bowel movements.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): difficulty breathing, swelling of face or throat. - Clostridioides difficile infection: persistent watery diarrhea with abdominal pain. - Low magnesium levels (hypomagnesemia): muscle cramps, irregular heartbeat. - Bone fractures: increased risk with long‑term use, especially in the elderly. - Liver enzyme elevation: abnormal liver function tests indicating possible hepatic stress.

When prescribing Pantoprazole Stada, clinicians should consider several safety aspects. - Assess renal and hepatic function: dose adjustment may be required in severe impairment. - Review concomitant medications: potential for drug‑drug interactions, especially with antiplatelet agents. - Monitor long‑term users: watch for signs of vitamin B12 deficiency and bone density loss. - Use caution in pregnancy: only if the potential benefit outweighs the risk. - Avoid in known hypersensitivity: discontinue if allergic reactions occur. - Store at ambient temperature: keep below 25°C, in the original packaging, protected from moisture.

Pantoprazole can affect the pharmacokinetics of several co‑administered drugs.

Major Interactions (Avoid): - Antiplatelet agents (e.g., clopidogrel): reduced activation may diminish antiplatelet effect. - HIV protease inhibitors (e.g., atazanavir): decreased absorption leading to sub‑therapeutic levels.

Moderate Interactions (Monitor Closely): - Warfarin: potential increase in INR, requiring more frequent monitoring. - Methotrexate: reduced renal clearance may raise serum concentrations. - Digoxin: higher plasma levels possible, necessitating dose review. - Oral contraceptives: slight reduction in efficacy, advise backup contraception.